Evidence map›Paper›PMID 38791934›Full record

ArticleCancers2024

Characterization of

Eric Ovruchesky, Elizabeth Pan, Melis Guer, Andrew Elliott, Shankar Siva, Praful Ravi, Bradley McGregor, Aditya Bagrodia, Ithaar Derweesh, Pedro Barata and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Eric OvrucheskyDivision of Urologic Oncology, Department of Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Elizabeth PanDivision of Urologic Oncology, Department of Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Melis GuerDivision of Urologic Oncology, Department of Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Andrew ElliottDepartment of Clinical and Translational Research, Caris Life Sciences, Inc., Phoenix, AZ 85040, USA.ORCID 0000-0001-8494-8031
Shankar SivaDivision of Radiation Oncology and Cancer Imaging, Department of Oncology, Peter MacCallum Cancer Centre, the University of Melbourne, Melbourne, VIC 3052, Australia.ORCID 0000-0003-2840-0658
Praful RaviThe Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Bradley McGregorThe Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-8298-0289
Aditya BagrodiaDivision of Urologic Oncology, Department of Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Ithaar DerweeshDivision of Urologic Oncology, Department of Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Pedro BarataDepartment of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA.ORCID 0000-0002-8890-2951
Elisabeth I HeathDepartment of Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI 48201, USA.ORCID 0000-0003-1381-2713
Emmanuel S AntonarakisDepartment of Hematology and Oncology, University of Minnesota, Masonic Cancer Center, Minneapolis, MN 55455, USA.ORCID 0000-0003-3531-3851
Sourat DarabiClinical Genomics, Hoag Family Cancer Institute, Newport Beach, CA 92663, USA.ORCID 0000-0002-3395-894X
Dave S B HoonDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Providence Health Systems, Santa Monica, CA 90404, USA.
Amir MortazaviDivision of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, The Comprehensive Cancer Center, Columbus, OH 43210, USA.
Toni K ChoueiriThe Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Chadi NabhanDepartment of Clinical and Translational Research, Caris Life Sciences, Inc., Phoenix, AZ 85040, USA.
Shuanzeng WeiDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Rana R McKayDivision of Urologic Oncology, Department of Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
NCI NIH HHS P30 CA077598NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

purposeGiven the emergence of PSMA-targeted diagnostic agents and therapeutics, we sought to investigate patterns of

methodsWe conducted a pooled multi-institutional analysis of patients with RCC having undergone DNA and RNA next-generation sequencing.

resultsWe included 1,724 patients in the analysis. FOLH1 expression was significantly higher in clear cell (71%) compared to non-clear cell RCC tumors (19.0 versus 3.3 TPM,

conclusionsWe observed differential patterns of

Indexed as

diagnosticsFOLH1molecular profilingrenal cell carcinomatherapeutics

Identifiers

PMID38791934
PMCPMC11119455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.